Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TORL-3-600 in advanced solid tumors
NCT05948826Phase 1Active, not recruiting
- Sponsor
- TORL BioTherapeutics
- Start
- Sep 2023
- Primary completion
- Jun 2026
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 2
01
Overview
Phase 1, open-label trial of TORL-3600 in solid tumor (advanced stage) and colorectal cancer (CRC) (2 arms), sponsored by TORL BioTherapeutics. Primary endpoints: Adverse Events at 2 years, Maximum Tolerated Dose at 28 days and 1 more. Started Sep 2023; status: active, not recruiting.
02
Drugs
TORL-3600
03
Conditions
solid tumor (advanced stage)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05948826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05948826.